Quick Answer
Telomir Pharmaceuticals, Inc. reported Net Income of -$10.41 million for fiscal year 2025.
Telomir Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net Income | -$10.41M +37.0% |
-$16.53M -26.5% |
-$13.07M -1430.4% |
-$854.1K | — |
| Diluted EPS | -$0.33 +41.1% |
-$0.56 -216.7% |
$0.48 +1700.0% |
-$0.03 | — |
| Total Assets | $7.34M +454.5% |
$1.32M -72.3% |
$4.77M +9696.4% |
$48.7K | — |
| Stockholders Equity | $5.91M +819.6% |
$643.0K -81.3% |
$3.44M +466.8% |
-$937.3K -578.5% |
-$138.1K |
| R&D Expense | $2.44M +9.0% |
$2.24M +42.0% |
$1.57M +88.9% |
$833.2K | — |
| Shares Outstanding | 34.38M +15.5% |
29.76M +4.0% |
28.61M +6.6% |
26.83M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$1.10M | +81.6% | +78.3% |
| Diluted EPS | September 30, 2025 | -$0.03 | +85.0% | -117.6% |
| Total Assets | September 30, 2025 | $7.40M | +610.4% | +792.2% |
| Cash and Equivalents | June 30, 2025 | $754.3K | — | +87.2% |
| Stockholders Equity | September 30, 2025 | $6.98M | +1478.8% | +1350.3% |
| R&D Expense | September 30, 2025 | $759.5K | +21.1% | +1673.0% |
| Shares Outstanding | September 30, 2025 | 33.83M | +14.3% | +10.9% |
- Telomir Pharmaceuticals, Inc. reported Net Income of -$10.41 million for fiscal year 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +37.0% in Net Income compared to the prior fiscal year.
- Telomir Pharmaceuticals, Inc. reported Diluted EPS of $0.33 per share (loss) for fiscal year 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +41.1% in Diluted EPS compared to the prior fiscal year.
- Telomir Pharmaceuticals, Inc. reported Total Assets of $7.34 million for fiscal year 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +454.5% in Total Assets compared to the prior fiscal year.
- Telomir Pharmaceuticals, Inc. reported Stockholders Equity of $5.91 million for fiscal year 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +819.6% in Stockholders Equity compared to the prior fiscal year.
- Telomir Pharmaceuticals, Inc. reported R&D Expense of $2.44 million for fiscal year 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +9.0% in R&D Expense compared to the prior fiscal year.
- Telomir Pharmaceuticals, Inc. reported Shares Outstanding of 34.38 million shares for fiscal year 2025.
- Telomir Pharmaceuticals, Inc. showed an increase of +15.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: